2023 World Conference on Lung Cancer (Posters)-P2.03. Clinical Impact of Genomic Characterization in Induced Oligometastatic Non-small Cell Lung Cancer

Pdf Summary

A study was conducted to assess the genomic characteristics of induced oligometastatic non-small cell lung cancer (NSCLC) and its implications for treatment decisions. The study included patients with advanced NSCLC who had received systemic therapy and were diagnosed with oligometastasis. Tumor tissues were collected from these patients and subjected to whole-exome sequencing.<br /><br />The findings of the study showed that resistance to targeted therapy, intratumoral heterogeneity (ITH), and genomic instability driven by homologous recombination deficiency (HRD) contribute to the persistence and recurrence of oligometastatic lesions in advanced NSCLC. Increased ITH and HRD events were associated with poorer clinical outcomes.<br /><br />The study also identified the most frequently mutated genes after systemic therapy, which included EGFR, TP53, PIK3CA, and MUC17. Somatic copy number gain was observed at specific regions. Potential acquired resistance alterations to targeted therapies were also identified.<br /><br />The analysis of intratumoral heterogeneity showed that it was positively correlated with tumor mutation burden and tumor neoantigen burden. Patients with high intratumoral heterogeneity had a reduced progression-free survival compared to those with low intratumoral heterogeneity.<br /><br />Furthermore, the study evaluated the homologous recombination deficiency status of primary lesions. There was a positive correlation between HRDscore and the duration of systemic therapy. Patients with a higher HRDscore had a significantly reduced progression-free survival compared to those with a lower HRDscore.<br /><br />Overall, these findings suggest that a comprehensive understanding of the genomic characteristics of induced oligometastatic NSCLC can help improve treatment strategies after local consolidation therapy and after the development of drug resistance. Targeting resistance mechanisms and addressing intratumoral heterogeneity and genomic instability may lead to better clinical outcomes in patients with oligometastatic NSCLC.

Asset Subtitle

Rui Fu

Meta Tag

Speaker Rui Fu

Topic Metastatic NSCLC: Local Therapies

Keywords

genomic characteristics

induced oligometastatic NSCLC

systemic therapy

intratumoral heterogeneity

homologous recombination deficiency

clinical outcomes

frequently mutated genes

acquired resistance alterations

tumor mutation burden

progression-free survival